NCT04383210: A Phase 2 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER3
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a tumor that expresses an NRG1 gene fusion
Exclusions: Patients with untreated or symptomatic brain metastases that require treatment – see trial for details; Patients with prior treatment of ERBB3/HER3 directed therapy

Comments are closed.

Up ↑